Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
227.40
-1.00 (-0.44%)
At close: Dec 16, 2025, 4:00 PM EST
227.18
-0.22 (-0.10%)
After-hours: Dec 16, 2025, 7:42 PM EST
Natera Employees
Natera had 4,434 employees as of December 31, 2024. The number of employees increased by 1,141 or 34.65% compared to the previous year.
Employees
4,434
Change (1Y)
1,141
Growth (1Y)
34.65%
Revenue / Employee
$477,374
Profits / Employee
-$69,731
Market Cap
31.45B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
| Dec 31, 2023 | 3,293 | 275 | 9.11% |
| Dec 31, 2022 | 3,018 | 348 | 13.03% |
| Dec 31, 2021 | 2,670 | 855 | 47.11% |
| Dec 31, 2020 | 1,815 | 776 | 74.69% |
| Dec 31, 2019 | 1,039 | 64 | 6.56% |
| Dec 31, 2018 | 975 | 82 | 9.18% |
| Dec 31, 2017 | 893 | 41 | 4.81% |
| Dec 31, 2016 | 852 | 136 | 18.99% |
| Dec 31, 2015 | 716 | 42 | 6.23% |
| Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NTRA News
- 17 hours ago - I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer - Business Wire
- 4 days ago - Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer - Business Wire
- 5 days ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 6 days ago - Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer - Business Wire
- 7 days ago - Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting - Business Wire
- 11 days ago - Natera Acquires Foresight Diagnostics - Business Wire
- 13 days ago - New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting - Business Wire
- 14 days ago - Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium - Business Wire